Blueprint Medicines, a Sanofi company, today announced AYVAKIT(R) (avapritinib) data showing clinically meaningful outcomes and a w ...

Patients with indolent mastocytosis may express concern about anaphylaxis or milder reactions to various substances, but Dr. Aaron T. Gerds, of Cleveland Clinic, reminds them that "you can't go into a ...

Aaron T. Gerds, MD, MS, Associate Professor of Medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of Medicine, talks about patient factors to consider ...

When Bob was first diagnosed and treated for follicular lymphoma, he refused to let the fear of the cancer returning dominate his life. Nearly 25 years later—after having experienced a relapse—Bob is ...

Editor's note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. So, there are a number of things that set ...

Indolent CD4+ cytotoxic chimeric antigen receptor (CAR) T-cell lymphoma involving the small intestine was diagnosed in a patient who had previously received ciltacabtagene autoleucel (cilta-cel) CAR T ...

In the complex world of rare diseases, even small advances in understanding can make a profound difference in patients’ lives. Medscape Live is bringing back-to-back educational programs to San Diego ...

Please provide your email address to receive an email when new articles are posted on . Axicabtagene ciloleucel induced durable responses for patients with relapsed or refractory indolent non-Hodgkin ...